Concerns regarding in vitro and in vivo uses of thalidomide [1]

Leprosy Review

Volumn 76, Issue 1, 2005, Pages 94-96

  Tadesse, Azeb ^a,b   Shannon, E J ^b  

^a ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; LEPROSTATIC AGENT;

CELL LEVEL; CELL STIMULATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG INDICATION; DRUG MECHANISM; ERYTHEMA NODOSUM LEPROSUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETTER; NONHUMAN; PHENOTYPE; REVERSAL REACTION; SIDE EFFECT; TERATOGENESIS; TOXIC EPIDERMAL NECROLYSIS; ERYTHEMA NODOSUM; LEPROMATOUS LEPROSY;

ERYTHEMA NODOSUM; HUMANS; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; THALIDOMIDE;

EID: 19844371787     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (23)

1. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Int J Dermatol, 1980; 19: 318-322.
2. Hastings RC. Leprosy. Churchill Livingstone. Edinburgh London Melbourne, New York 1985.
3. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med, 1991; 173: 699-703.
4. Nashimura K, Hashimoto Y, Iwasaki S. Enhancement of phorbol ester-induced production of tumor necrosis α by thalidomide. Biochem Biophys Res Commun, 1994; 199: 455-460.
5. Shannon EJ, Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells. Immunopharmacol Immunotoxicol, 1996; 18: 59-72.
6. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol, 2001; 57: 365-376.
7. The Merck Index. Merck and Co. Inc., Whitehouse station, NJ, USA, 12th edn, 1996.
8. Shannon EJ, Sandoval F, Krahenbuhl JL. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α. Immunopharmacology, 1997; 36:9-15.
9. Günzler V, Hanauske-Able HM, Tschank G, Schulte-Wessermann H. Immunological effects of thalidomide. Arzeineim-Forsch Drug Res, 1986; 7: 1138-1141.
10. Williams RT. Thalidomide, a study of biochemical teratology. Arch Environ Health, 1968; 16: 493-502.
11. + T-cells. Clin Exp Immunol, 2002; 130: 75-84.
12. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology, 1995; 31: 109-116.
13. Shannon EJ, Aseffa A, Pankey G, Sandoval F. Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology, 2000; 46: 175-179.
14. 3]-thymidine - dependence on the the primary stimulant. Immunopharmacology, 2002; 2: 1143-1153.
15. Sampaio E, Kaplan G, Miranda A et al. The influence of thalidomide on clinical and immunological manifestations of erythema nodosum leprosum. J Infect Dis, 1993; 168: 408-414.
16. Jacobson J, Greenspan J, Spritzler J et al. Thalidomide for the treatment of oral apthous ulcers in patients with immunodeficiency virus infection. N Engl J Med, 1997; 336: 1487-1493.
17. Wolkenstein P, Latarjet J, Roujeau J, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet, 1998; 352: 1586-1589.
18. Moreira A, Wang J, Sarno E, Kapan G. Thalidomide protects mice against LPS-induced shock. Braz J Med Bio Res, 1997; 30: 1199-1207.
19. Arrieta O, Oritiz-Reyes A, Rembao D et al. Protective effect of pentoxifylline plus thalidomide against septic shock in mice. Int J Exp Pathol, 1999; 80: 11-16.
20. Ishikawa M, Kanno S, Takayangi M et al. Thalidomide promotes the release of tumor necrosis factor-α (TNF-α) and lethality by lipopolysaccharide in mice. Bio Pharm Bull, 1998; 21: 638-640.
21. Morieira A, Kaplan G, Villahermosa L et al. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int J Lepr, 1998; 65: 638-640.
22. Gru G, Shremants K, Pointaire P et al. TNF and mycobacteria in tumor necosis factors: the molecules and their emerging role in medicine. Raven Press Ltd, New York 1992.
23. Khanolkar-Young S, Rayment N, Brickell P et al. Tumor necrosis factor-α (TNF-α) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol, 1995; 99: 196-202.